Hoth Therapeutics updates corporate presentation with clinical milestones and cash position

Hoth Therapeutics, Inc.

HT-001 Phase 2a open-label cohort showed promising results; case study published Sept 2024.
HT-KIT IND-enabling tox studies initiated Q1 2024; target IND submission Q4 2026.
HT-ALZ patent awarded Q3 2024; preclinical studies at Washington University completed.
HT-VA license from Veteran's Affairs obtained Q1 2025; CRADA executed Q2 2025.
15.4M shares outstanding as of Oct 14, 2025; cash sufficient for clinical and preclinical programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.